Onishi T, Machida T, Masuda F, Torii S, Shirakawa H, Hatano T, Makino H
Department of Urology, Jikei University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1991 Nov;82(11):1800-6. doi: 10.5980/jpnjurol1989.82.1800.
The immunological study of the major histocompatibility complex (class I, class II and DR antigens), tumour infiltrating lymphocytes (TIL), regional lymph node lymphocytes (RLNL) and peripheral blood lymphocytes (PBL) was evaluated on the basis of immunohistochemical staining using monoclonal antibodies of each subset of lymphocytes in a series of 16 patients with renal cell carcinoma. Two renal cell carcinomas in dialysis patients with acquired cystic disease of the kidneys (ACDK) were also included in this study. With regard to the immunological environment, a comparative study between renal cell carcinoma accompanied with ACDK and 14 other renal cell carcinoma was carried out. The results are described below: 1) With regard to the expression of MHC antigens in tumour cells, the degrees of expression of MHC class I, class II and DR-antigen in case 1 were higher than that of the other 14 renal cell carcinomas. On the other hand, no expression of MHC was detected in case 2. 2) As to the subsets of TIL, the CD25 (IL-2 receptor) was not expressed in all the renal cell carcinoma. As to the T cell receptor (TCR-alpha/beta chain), the degree of expression was the same in case 1 and the other 14 cases. On the other hand, no TCR was detected in the case 2. As to the other subsets of TIL (CD3, CD4, CD8, CD16 and CD20), the rates of the infiltration were the same in case 1 and the other 14 cases, but those in case 2 were lesser than in all other 14 cases.(ABSTRACT TRUNCATED AT 250 WORDS)
在16例肾细胞癌患者中，使用淋巴细胞各亚群的单克隆抗体，通过免疫组织化学染色对主要组织相容性复合体（I类、II类和DR抗原）、肿瘤浸润淋巴细胞（TIL）、区域淋巴结淋巴细胞（RLNL）和外周血淋巴细胞（PBL）进行了免疫学研究。本研究还纳入了2例患有获得性肾囊肿病（ACDK）的透析患者的肾细胞癌。关于免疫环境，对伴有ACDK的肾细胞癌与其他14例肾细胞癌进行了对比研究。结果如下：1）关于肿瘤细胞中MHC抗原的表达，病例1中MHC I类、II类和DR抗原的表达程度高于其他14例肾细胞癌。另一方面，病例2中未检测到MHC的表达。2）至于TIL的亚群，所有肾细胞癌中均未检测到CD25（IL-2受体）的表达。至于T细胞受体（TCR-α/β链），病例1和其他14例中的表达程度相同。另一方面，病例2中未检测到TCR。至于TIL的其他亚群（CD3、CD4、CD8、CD16和CD20），病例1和其他14例中的浸润率相同，但病例2中的浸润率低于其他所有14例。（摘要截选于250词）
